The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer
Official Title: A Two-part, Placebo-controlled, Study of the Safety and Efficacy of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Have Inadequate Analgesia Even With Optimized Chronic Opioid Therapy.
Study ID: NCT01424566
Brief Summary: The primary objective of this study was to evaluate the efficacy of nabiximols (Sativex®), compared with placebo, when used as an adjunctive measure in relieving uncontrolled persistent chronic pain (not breakthrough pain) in participants with advanced cancer, who had inadequate analgesia even with optimized chronic opioid therapy. This multi-center study was conducted in two parts. All participants enrolled into the trial received nabiximols during one of two parts of the study, but they did not know which part. Eligible participants were not required to stop any of their current treatments or medications.
Detailed Description: This 11-week, multi-center, placebo-controlled study aimed to determine the efficacy, safety and tolerability of nabiximols administered as an adjunctive treatment for 5 weeks, versus placebo, assessed by a 2-part, randomized withdrawal design. The first part of the study (Part A) was single-blind (participants) and the second part of the study (Part B) was randomized, double-blind. Eligible participants had advanced cancer, with a clinical diagnosis of cancer related pain which was not wholly alleviated by their current optimized opioid treatment. Qualifying participants entered the study at screening and commenced a 5- to 14-day eligibility period. During this period, eligible participants had 3 consecutive days where pain severity remained within defined parameters, break-through opioid usage had not exceeded an average of 4 episodes per day, and maintenance opioid medication and dose had not changed. Eligible participants underwent nabiximols titration during a single-blind treatment period lasting 10 days, followed by 4 days of therapy at the titrated dose. Participants who demonstrated an improvement of 15% or more on the score of the pain numerical rating scale were advanced to Part B, where they were randomized 1:1 to nabiximols or placebo in a double-blind fashion. Participants then received study treatments at their self-titrated doses for 5 weeks. After the end of the 5-week treatment period, participants were offered the option of entering an open-label extension (OLE) study; participants who entered the OLE up to 7 days after study completion had their follow-up assessments performed on the same day as their first OLE study visit. Participants that did not enter the OLE study had a safety follow up visit 14 days after treatment completion, which could be via telephone.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
, East Melbourne, , Australia
, Parkville, , Australia
, Shumen, , Bulgaria
, Varna, , Bulgaria
, Vratsa, , Bulgaria
, Lunen, , Germany
, Stadtroda, , Germany
, Wetzlar, , Germany
, Budapest, , Hungary
, Deszk, , Hungary
, Komárom, , Hungary
, Nyíregyháza, , Hungary
, Szikszó, , Hungary
, Bangalore, , India
, Jaipur, , India
, Pune, , India
, Ashkelon, , Israel
, Beer Sheva, , Israel
, Haifa, , Israel
, Jerusalem, , Israel
, Ramat Gan, , Israel
, Zerifin, , Israel
, Garbagnate Milanese, , Italy
, Piacenza, , Italy
, Torino, , Italy
, Klaipeda, , Lithuania
, Siauliai, , Lithuania
, Vilnius, , Lithuania
, Bydgoszcz, , Poland
, Czeladź, , Poland
, Gdansk, , Poland
, Gliwice, , Poland
, Klodzko, , Poland
, Opole, , Poland
, Ostrowiec Swietokrzyski, , Poland
, Poznan, , Poland
, Warszawa, , Poland
, Warszawa, , Poland
, Wloclawek, , Poland
, Alba Iulia, , Romania
, Baia Mare, , Romania
, Braila, , Romania
, Bucuresti, , Romania
, Focșani, , Romania
, Oradea, , Romania
, Satu Mare, , Romania
, Sibiu, , Romania
, Suceava, , Romania
, Cadiz, , Spain
, Granada, , Spain
, Madrid, , Spain
, Salamanca, , Spain
, Sevilla, , Spain
, Changhua City, , Taiwan
, Taichung, , Taiwan
, Tainan City, , Taiwan
, Taipei, , Taiwan
, Taipei, , Taiwan
, Taipei, , Taiwan
, Taipei, , Taiwan
, Bury Saint Edmunds, , United Kingdom
, Edinburgh, , United Kingdom
, Glasgow, , United Kingdom
, Manchester, , United Kingdom
, Norwich, , United Kingdom